公开(公告)号：US10364267B2

公开(公告)日：2019-07-30

申请号：US15439358

申请日：2017-02-22

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Jiang Long ,  Guoyou Xu ,  Peng Dai ,  Ruichao Shen ,  Xuechao Xing ,  Jing He

IPC: C07B59/00 ,  C07J41/00 ,  C07J9/00

Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

公开(公告)号：US20170334893A1

公开(公告)日：2017-11-23

申请号：US15597417

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Jun Ma ,  Bin Wang ,  Yong He ,  Xuechao Xing ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Jiang Long ,  Guoqiang Wang

IPC: C07D413/12 ,  C07D261/08

CPC classification number: C07D413/12 ,  A61K31/42 ,  C07D261/08

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US20170304270A1

公开(公告)日：2017-10-26

申请号：US15497268

申请日：2017-04-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Brett Granger ,  Ruichao Shen ,  Xuechao Xing ,  Bin Wang ,  Jun Ma ,  Jing He ,  Jiang Long ,  Yong He ,  Guoqiang Wang

IPC: A61K31/42 ,  C07D261/06 ,  C07D413/04 ,  C07D413/12

CPC classification number: A61K31/42 ,  C07D261/06 ,  C07D261/08 ,  C07D413/04 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US20170240587A1

公开(公告)日：2017-08-24

申请号：US15439531

申请日：2017-02-22

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yat Sun Or ,  Jing He ,  Guoqiang Wang ,  Xuechao Xing

IPC: C07J43/00

CPC classification number: C07J43/003 ,  A61K31/58 ,  C07J9/005 ,  C07J41/0061

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

公开(公告)号：US20230416268A1

公开(公告)日：2023-12-28

申请号：US18139506

申请日：2023-04-26

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yat Sun Or ,  Joseph D. Panarese ,  Guoqiang Wang ,  Jing He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Sourav Ghorai

IPC: C07D495/04

CPC classification number: C07D495/04

Abstract: The present invention provides compounds of Formula (I),




pharmaceutical compositions comprising these compounds and methods of using these compounds for treating a metabolic disease or liver condition. The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

公开(公告)号：US20210261600A1

公开(公告)日：2021-08-26

申请号：US17186447

申请日：2021-02-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Jiang Long ,  Peng Dai ,  Xuechao Xing ,  Jing He

IPC: C07J41/00 ,  C07J43/00

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10968249B2

公开(公告)日：2021-04-06

申请号：US16878329

申请日：2020-05-19

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Jiang Long ,  Peng Dai ,  Xuechao Xing ,  Jing He

IPC: C07J41/00 ,  C07J43/00 ,  C07J9/00 ,  C07J51/00

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US20190337935A1

公开(公告)日：2019-11-07

申请号：US16400498

申请日：2019-05-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis disease (NASH).

公开(公告)号：US10450306B2

公开(公告)日：2019-10-22

申请号：US15724919

申请日：2017-10-04

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jun Ma ,  Guoqiang Wang ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D261/08 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10450301B2

公开(公告)日：2019-10-22

申请号：US15988806

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: A61K31/4375 ,  A61K31/4725 ,  C07D401/14 ,  C07D471/04 ,  C07D471/08 ,  C07D417/14 ,  C07D451/02 ,  C07D451/06

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).